{"nctId":"NCT05691712","briefTitle":"A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes","startDateStruct":{"date":"2023-02-05","type":"ACTUAL"},"conditions":["Diabetes Type 2","Diabetes Mellitus","Glucose Metabolism Disorders","Metabolic Disease","Endocrine System Diseases"],"count":257,"armGroups":[{"label":"5 Milligram (mg) Tirzepatide","type":"EXPERIMENTAL","interventionNames":["Drug: Tirzepatide"]},{"label":"10 mg Tirzepatide","type":"EXPERIMENTAL","interventionNames":["Drug: Tirzepatide"]},{"label":"15 mg Tirzepatide","type":"EXPERIMENTAL","interventionNames":["Drug: Tirzepatide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tirzepatide","otherNames":["LY3298176"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have type 2 diabetes mellitus (T2DM)\n* Have HbA1c ≥7.0% (53 mmol/mol) to ≤11% (97 mmol/mol)\n* Have been treated with insulin glargine (U100) once daily alone, or in combination with metformin with or without SGLT-2i ≥90 days\n* Have a body mass index (BMI) ≥23 kilograms per meter squared (kg/m²)\n\nExclusion Criteria:\n\n* Have type 1 diabetes mellitus (T1DM)\n* Have a history of chronic or acute pancreatitis\n* Have proliferative diabetic retinopathy or diabetic macular edema or nonproliferative diabetic retinopathy that requires acute treatment\n* Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2\n* Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months\n* Have a history of diabetic ketoacidosis or hyperosmolar state/coma within the 6 months\n* Have acute myocardial infarction, or cerebrovascular accident (stroke) or hospitalization due to congestive heart failure (CHF) in the past 2 months\n* Have a serum calcitonin level of ≥35 ng/L, as determined by central laboratory\n* Have acute or chronic hepatitis, signs, and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) level \\>3.0 times the upper limit of normal (ULN), as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial only if their ALT level is ≤3.0 times ULN.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg])","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.1","spread":"1.367"},{"groupId":"OG001","value":"-25.9","spread":"1.386"},{"groupId":"OG002","value":"-9.96","spread":"1.340"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in HbA1c (Tirzepatide 5 mg)","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was calculated using MMRM for post-baseline measures: Variable = Baseline + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.0","spread":"1.329"},{"groupId":"OG001","value":"-9.96","spread":"1.340"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Body Weight","description":"LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Baseline HbA1c (\\<=8.0%, \\>8.0%) + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"0.52"},{"groupId":"OG001","value":"-4.8","spread":"0.54"},{"groupId":"OG002","value":"-4.3","spread":"0.55"},{"groupId":"OG003","value":"1.7","spread":"0.53"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c <7.0% (53 Millimole/Mole [mmol/Mol]) and ≤6.5% (48 mmol/Mol)","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Percentage of Participants with HbA1c \\<7.0% (53 millimole/mole \\[mmol/mol\\]) and ≤6.5% (48 mmol/mol) is reported here.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.81","spread":null},{"groupId":"OG001","value":"78.95","spread":null},{"groupId":"OG002","value":"78.18","spread":null},{"groupId":"OG003","value":"17.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.68","spread":null},{"groupId":"OG001","value":"77.19","spread":null},{"groupId":"OG002","value":"69.09","spread":null},{"groupId":"OG003","value":"6.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Fasting Serum Glucose","description":"LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Baseline HbA1c (\\<=8.0%, \\>8.0%) + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.5","spread":"3.73"},{"groupId":"OG001","value":"-52.5","spread":"3.87"},{"groupId":"OG002","value":"-51.0","spread":"3.94"},{"groupId":"OG003","value":"-23.7","spread":"3.84"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c <5.7% (39 mmol/Mol) [Tirzepatide 10 mg or 15 mg]","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Percentage of participants with HbA1c \\<5.7% (39 mmol/Mol) is reported here.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.54","spread":null},{"groupId":"OG001","value":"25.45","spread":null},{"groupId":"OG002","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c <5.7% (39 mmol/Mol) [Tirzepatide 5 mg]","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Percentage of participants with HbA1c \\<5.7% (39 mmol/Mol) is reported here.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.68","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Daily Average 7-point Self-monitored Blood Glucose Profiles","description":"The SMBG data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post meal, Midday Premeal, Midday 2-hour Post meal, Evening Premeal, Evening 2-hour Post meal and Bedtime. The daily average was calculated as the average of the 7 blood glucose values collected on a particular day. LS Mean was calculated using MMRM for post-baseline measures: Variable = Baseline + Baseline HbA1c (\\<=8.0%, \\>8.0%) + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.62","spread":"0.127"},{"groupId":"OG001","value":"-2.53","spread":"0.132"},{"groupId":"OG002","value":"-2.80","spread":"0.136"},{"groupId":"OG003","value":"-2.22","spread":"0.131"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.78","spread":"0.300"},{"groupId":"OG001","value":"-5.34","spread":"0.306"},{"groupId":"OG002","value":"-5.05","spread":"0.313"},{"groupId":"OG003","value":"-2.57","spread":"0.300"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.87","spread":"0.247"},{"groupId":"OG001","value":"-3.52","spread":"0.258"},{"groupId":"OG002","value":"-3.26","spread":"0.263"},{"groupId":"OG003","value":"-1.32","spread":"0.253"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.05","spread":"0.318"},{"groupId":"OG001","value":"-4.10","spread":"0.325"},{"groupId":"OG002","value":"-3.65","spread":"0.335"},{"groupId":"OG003","value":"-1.46","spread":"0.322"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.84","spread":"0.264"},{"groupId":"OG001","value":"-3.64","spread":"0.276"},{"groupId":"OG002","value":"-3.20","spread":"0.285"},{"groupId":"OG003","value":"-0.95","spread":"0.271"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.97","spread":"0.347"},{"groupId":"OG001","value":"-4.52","spread":"0.351"},{"groupId":"OG002","value":"-4.42","spread":"0.367"},{"groupId":"OG003","value":"-1.47","spread":"0.346"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.41","spread":"0.287"},{"groupId":"OG001","value":"-4.19","spread":"0.297"},{"groupId":"OG002","value":"-3.85","spread":"0.307"},{"groupId":"OG003","value":"-1.71","spread":"0.298"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Weight Loss of ≥5%","description":"Percentage of Participants who Achieved Weight Loss ≥5% is reported here.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.81","spread":null},{"groupId":"OG001","value":"49.12","spread":null},{"groupId":"OG002","value":"60.00","spread":null},{"groupId":"OG003","value":"1.72","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Weight Loss of ≥10%","description":"Percentage of Participants who Achieved Weight Loss ≥10% is reported here.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.06","spread":null},{"groupId":"OG001","value":"21.05","spread":null},{"groupId":"OG002","value":"25.45","spread":null},{"groupId":"OG003","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Weight Loss of ≥15%","description":"Percentage of Participants who Achieved Weight Loss ≥15% is reported here.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.84","spread":null},{"groupId":"OG001","value":"5.26","spread":null},{"groupId":"OG002","value":"9.09","spread":null},{"groupId":"OG003","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Daily Mean Insulin Glargine Dose","description":"LS Mean was calculated using MMRM for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Baseline HbA1c (\\<=8.0%, \\>8.0%) + SGLT2i Use (Yes/No) + Treatment + Time + Treatment\\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.90","spread":"6.424"},{"groupId":"OG001","value":"21.95","spread":"6.471"},{"groupId":"OG002","value":"18.21","spread":"6.364"},{"groupId":"OG003","value":"69.28","spread":"8.826"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c <7.0%, Without Weight Gain (<0.1 Kilogram [kg]) and Without Hypoglycemia, (Blood Glucose <3.0 mmol/L <54 Milligram/Deciliter [mg/dL])","description":"Percentage of Participants with HbA1c \\<7.0%, Without Weight Gain (\\<0.1 Kilogram \\[kg\\]) and Without Hypoglycemia, (Blood Glucose \\<3.0 mmol/L \\<54 Milligram/Deciliter \\[mg/dL\\]) is reported here","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.68","spread":null},{"groupId":"OG001","value":"70.18","spread":null},{"groupId":"OG002","value":"67.27","spread":null},{"groupId":"OG003","value":"5.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c ≤6.5%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood Glucose <3.0 mmol/L [54 mg/dL])","description":"Percentage of Participants with HbA1c ≤6.5%, Without Weight Gain \\<0.1 kg and Without Hypoglycemia (Blood glucose \\<3.0 mmol/L \\[54 mg/dL\\]) is reported here.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.77","spread":null},{"groupId":"OG001","value":"70.18","spread":null},{"groupId":"OG002","value":"61.82","spread":null},{"groupId":"OG003","value":"1.72","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c <7.0%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood Glucose <3.9 mmol/L [70 mg/dL] or Severe Hypoglycemia)","description":"Percentage of Participants with HbA1c \\<7.0%, Without Weight Gain \\<0.1 kg and Without Hypoglycemia (Blood Glucose \\<3.9 mmol/L \\[70 mg/dL\\] or Severe Hypoglycemia) is reported here.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.61","spread":null},{"groupId":"OG001","value":"57.89","spread":null},{"groupId":"OG002","value":"47.27","spread":null},{"groupId":"OG003","value":"5.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c ≤6.5%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood Glucose <3.9 mmol/L [70 mg/dL] or Severe Hypoglycemia)","description":"Percentage of Participants with HbA1c ≤6.5%, Without Weight Gain \\<0.1 kg and Without Hypoglycemia (Blood glucose \\<3.9 mmol/L \\[70 mg/dL\\] or Severe Hypoglycemia) is reported here.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.71","spread":null},{"groupId":"OG001","value":"57.89","spread":null},{"groupId":"OG002","value":"43.64","spread":null},{"groupId":"OG003","value":"1.72","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":65},"commonTop":["Diarrhoea","Decreased appetite","Upper respiratory tract infection","Lipase increased","Nausea"]}}}